Clinical Study of Venetoclax Combined with CACAG Regimen in the Treatment of Newly Diagnosed Acute Myeloid Leukemia

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 25, 2022

Primary Completion Date

August 14, 2023

Study Completion Date

August 14, 2024

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

azacytidine;cytarabine;aclamycin;Chidamide;venetoclax;granulocyte

"1. azacytidine (75 mg/m2/day, days 1 to 7).~2. cytarabine (75 mg/m2 bid, days 1 to 5).~3. aclamycin (10 mg/m2/day, day1,3,5).~4. Chidamide (30 mg/day , days 0,3).~5. venetoclax (100 mg day 1, 200 mg day 2, 400mg days 3 to 14 ).~6. granulocyte colony-stimulating factor (5ug/kg/day, day 0 until agranulocytosis recovery)"

Trial Locations (1)

100853

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Chinese PLA General Hospital

OTHER